JPWO2021020564A1 - - Google Patents
Info
- Publication number
- JPWO2021020564A1 JPWO2021020564A1 JP2021535464A JP2021535464A JPWO2021020564A1 JP WO2021020564 A1 JPWO2021020564 A1 JP WO2021020564A1 JP 2021535464 A JP2021535464 A JP 2021535464A JP 2021535464 A JP2021535464 A JP 2021535464A JP WO2021020564 A1 JPWO2021020564 A1 JP WO2021020564A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019142358 | 2019-08-01 | ||
| JP2019142358 | 2019-08-01 | ||
| PCT/JP2020/029446 WO2021020564A1 (ja) | 2019-08-01 | 2020-07-31 | Gd2結合性分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021020564A1 true JPWO2021020564A1 (cg-RX-API-DMAC7.html) | 2021-02-04 |
| JPWO2021020564A5 JPWO2021020564A5 (cg-RX-API-DMAC7.html) | 2022-06-01 |
| JP7505784B2 JP7505784B2 (ja) | 2024-06-25 |
Family
ID=74228907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535464A Active JP7505784B2 (ja) | 2019-08-01 | 2020-07-31 | Gd2結合性分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220275104A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4008347B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7505784B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001649A2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3031393T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021020564A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7521815B2 (ja) * | 2019-08-01 | 2024-07-24 | 国立大学法人三重大学 | 抗原受容体 |
| WO2023081485A1 (en) | 2021-11-08 | 2023-05-11 | Pacific Biosciences Of California, Inc. | Stepwise sequencing of a polynucleotide with a homogenous reaction mixture |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526785A (ja) * | 2008-06-30 | 2011-10-20 | モーフオテク・インコーポレーテツド | 抗gd2抗体並びにそれに関連する方法及び使用 |
| WO2012033885A1 (en) * | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| JP2013532968A (ja) * | 2010-06-19 | 2013-08-22 | メモリアル スローン−ケタリング キャンサー センター | 抗gd2抗体 |
| JP2015521607A (ja) * | 2012-06-18 | 2015-07-30 | アペイロン・バイオロジックス・アクチェンゲゼルシャフトAPEIRON Biologics AG | Gd2陽性癌を治療するための方法 |
| JP2017508466A (ja) * | 2014-03-06 | 2017-03-30 | ユーシーエル ビジネス ピーエルシー | キメラ抗原受容体 |
| WO2018023025A1 (en) * | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
| JP2022536341A (ja) * | 2019-06-13 | 2022-08-15 | アロジーン セラピューティクス,インコーポレイテッド | 抗talen抗体およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11248058B2 (en) * | 2015-02-19 | 2022-02-15 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
| EP3600357A4 (en) * | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| CN118853581A (zh) * | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| IT201800007601A1 (it) * | 2018-07-30 | 2020-01-30 | Rigenerand Srl | Metodo per la produzione di cellule bi-funzionali per il trattamento di tumori |
-
2020
- 2020-07-31 EP EP20845660.8A patent/EP4008347B1/en active Active
- 2020-07-31 ES ES20845660T patent/ES3031393T3/es active Active
- 2020-07-31 WO PCT/JP2020/029446 patent/WO2021020564A1/ja not_active Ceased
- 2020-07-31 US US17/631,745 patent/US20220275104A1/en active Pending
- 2020-07-31 BR BR112022001649A patent/BR112022001649A2/pt unknown
- 2020-07-31 JP JP2021535464A patent/JP7505784B2/ja active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526785A (ja) * | 2008-06-30 | 2011-10-20 | モーフオテク・インコーポレーテツド | 抗gd2抗体並びにそれに関連する方法及び使用 |
| JP2013532968A (ja) * | 2010-06-19 | 2013-08-22 | メモリアル スローン−ケタリング キャンサー センター | 抗gd2抗体 |
| WO2012033885A1 (en) * | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
| JP2015521607A (ja) * | 2012-06-18 | 2015-07-30 | アペイロン・バイオロジックス・アクチェンゲゼルシャフトAPEIRON Biologics AG | Gd2陽性癌を治療するための方法 |
| JP2017508466A (ja) * | 2014-03-06 | 2017-03-30 | ユーシーエル ビジネス ピーエルシー | キメラ抗原受容体 |
| WO2018023025A1 (en) * | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
| JP2022536341A (ja) * | 2019-06-13 | 2022-08-15 | アロジーン セラピューティクス,インコーポレイテッド | 抗talen抗体およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4008347A4 (en) | 2023-03-08 |
| ES3031393T3 (en) | 2025-07-08 |
| BR112022001649A2 (pt) | 2022-03-22 |
| US20220275104A1 (en) | 2022-09-01 |
| EP4008347B1 (en) | 2025-04-30 |
| EP4008347A1 (en) | 2022-06-08 |
| WO2021020564A1 (ja) | 2021-02-04 |
| JP7505784B2 (ja) | 2024-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019017762A2 (cg-RX-API-DMAC7.html) | ||
| BR112021008711A2 (cg-RX-API-DMAC7.html) | ||
| BR112019016141A2 (cg-RX-API-DMAC7.html) | ||
| AU2020104490A5 (cg-RX-API-DMAC7.html) | ||
| BR112021013944A2 (cg-RX-API-DMAC7.html) | ||
| BR112019016138A2 (cg-RX-API-DMAC7.html) | ||
| BR112019016142A2 (cg-RX-API-DMAC7.html) | ||
| BR112021012348A2 (cg-RX-API-DMAC7.html) | ||
| AT524962A5 (cg-RX-API-DMAC7.html) | ||
| BR112021013128A2 (cg-RX-API-DMAC7.html) | ||
| BR112019016136A2 (cg-RX-API-DMAC7.html) | ||
| BR102020025141B1 (pt) | Máquina elétrica girante eletronicamente comutada | |
| BR102020020816B1 (pt) | Veículo, e, método para controlar o movimento de ar através de um veículo com uma ventoinha do veículo | |
| BR102020020846B1 (pt) | Niveladora, e, método para serviço em uma niveladora | |
| BR112022006436B1 (pt) | Compensador de pressão e montagem compreendendo uma instalação submarina e tal compensador de pressão | |
| BR102020018650B1 (pt) | Método para preparar óxido de cálcio usando um forno pré- aquecedor de suspensão de múltiplos estágios | |
| BR102020017390B1 (pt) | Bomba multifásica | |
| BR102020016297B1 (pt) | Bolsa de forro para um contentor e método para criar e prender uma bolsa de forro a um contentor | |
| BR102020011722B1 (pt) | Porta de tela para um pacote de radiadores | |
| BR102020005984B1 (pt) | Dispositivo de arranque-gerador combinado, e, conjunto de trem de acionamento | |
| BR102020005860B1 (pt) | Controle de obstrução para um implemento agrícola | |
| BR112021012379B1 (pt) | Material de aço adequado para uso em ambiente ácido | |
| BR112021013352B1 (pt) | Processo e dispositivo para endireitar arame ou material de fita | |
| BR112021010564B1 (pt) | Sistema de armadilha para animais e método de monitoramento do mesmo | |
| BR112021014592B1 (pt) | Compostos fotosensibilizadores, métodos de fabricação e aplicação em plantas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20220119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230508 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240604 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240606 |